Q BioMed Inc (OTCQB:QBIO) has launched a Named Patient Program (NPP) to bring its non-opioid bone metastasis pain drug Strontium89 to patients around the world starting in September, the company announced on Tuesday.
Strontium89 is FDA-approved for the treatment of painful skeletal metastases caused by cancer, regardless of the type of tumor. Common cancers that metastasize to the bone include prostate, breast, lung and others.
The NPP allows Strontium89 to be provided to patients internationally without needing additional regulatory approval in their countries. It will be facilitated by Caligor Coghlan Pharma Services, a global pharmaceuticals company based in Texas.
READ: Q Biomed to scale-up production of potential liver cancer chemotherapeutic Uttroside-B as it gears up for IND filing
"We are very happy that Strontium89 is once again available worldwide, and that physicians have the ability to prescribe a safe, effective and non-opioid treatment to their be metastasis pain patients regardless of their primary tumor type and notably beyond prostate cancer,” Q BioMed CEO Denis Corin said in a statement. “We are actively working to ensure that Strontium89 is accessible to patients everywhere and to extend its relevance and use thorough additional clinical study."
Strontium89 is administered intravenously once every three months and can reduce or even eliminate the need for opioid analgesics, the company said, delivering pain relief for 2-5 months in most patients.
In several multicenter, placebo-controlled trials of cancer patients with pain from bone metastases, relief occurred in more patients treated with a single injection of Strontium89 than in patients treated with an injection of placebo.
Contact Andrew Kessel at [email protected]
Follow him on Twitter @andrew_kessel